ZVRA Quote, Financials, Valuation and Earnings

Moleculin Biotech has a net margin of -15.19% compared to Zevra Therapeutics's net margin of --. Zevra Therapeutics's return on equity of -198.46% beat Moleculin Biotech's return on equity of --.

Zevra Therapeutics has a consensus price target of $22.75, signalling upside risk potential of 84.66%. On the other hand Moleculin Biotech has an analysts' consensus of $7.00 which suggests that it could grow by 993.75%. Given that Moleculin Biotech has higher upside potential than Zevra Therapeutics, analysts believe Moleculin Biotech is more attractive than Zevra Therapeutics.

Zevra Therapeutics has a beta of 1.965, which suggesting that the stock is 96.525% more volatile than S&P 500. In comparison Moleculin Biotech has a beta of 1.381, suggesting its more volatile than the S&P 500 by 38.119%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Moleculin Biotech quarterly revenues of --. Zevra Therapeutics's net income of -$3.1M is higher than Moleculin Biotech's net income of -$6.4M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.97x versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Macrogenics has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -311.07%. Zevra Therapeutics's return on equity of -198.46% beat Macrogenics's return on equity of -58.23%.

Zevra Therapeutics has a consensus price target of $22.75, signalling upside risk potential of 84.66%. On the other hand Macrogenics has an analysts' consensus of $4.20 which suggests that it could grow by 176.32%. Given that Macrogenics has higher upside potential than Zevra Therapeutics, analysts believe Macrogenics is more attractive than Zevra Therapeutics.

Zevra Therapeutics has a beta of 1.965, which suggesting that the stock is 96.525% more volatile than S&P 500. In comparison Macrogenics has a beta of 1.587, suggesting its more volatile than the S&P 500 by 58.67%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Macrogenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Macrogenics pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Macrogenics quarterly revenues of $13.2M. Zevra Therapeutics's net income of -$3.1M is higher than Macrogenics's net income of -$41M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Macrogenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.97x versus 0.63x for Macrogenics. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -271.3%. Zevra Therapeutics's return on equity of -198.46% beat Spero Therapeutics's return on equity of -108.26%.

Zevra Therapeutics has a consensus price target of $22.75, signalling upside risk potential of 84.66%. On the other hand Spero Therapeutics has an analysts' consensus of $5.00 which suggests that it could grow by 102.43%. Given that Spero Therapeutics has higher upside potential than Zevra Therapeutics, analysts believe Spero Therapeutics is more attractive than Zevra Therapeutics.

Zevra Therapeutics has a beta of 1.965, which suggesting that the stock is 96.525% more volatile than S&P 500. In comparison Spero Therapeutics has a beta of 1.331, suggesting its more volatile than the S&P 500 by 33.062%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Spero Therapeutics pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are larger than Spero Therapeutics quarterly revenues of $5.1M. Zevra Therapeutics's net income of -$3.1M is higher than Spero Therapeutics's net income of -$13.9M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Spero Therapeutics's PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.97x versus 4.76x for Spero Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -15.19% compared to Zevra Therapeutics's net margin of -15.34%. Zevra Therapeutics's return on equity of -198.46% beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Zevra Therapeutics has a consensus price target of $22.75, signalling upside risk potential of 84.66%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.10 which suggests that it could grow by 19.77%. Given that Zevra Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Zevra Therapeutics is more attractive than Xeris Biopharma Holdings.

Zevra Therapeutics has a beta of 1.965, which suggesting that the stock is 96.525% more volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 0.700, suggesting its less volatile than the S&P 500 by 29.996%.

Zevra Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zevra Therapeutics pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Zevra Therapeutics quarterly revenues are $20.4M, which are smaller than Xeris Biopharma Holdings quarterly revenues of $60.1M. Zevra Therapeutics's net income of -$3.1M is higher than Xeris Biopharma Holdings's net income of -$9.2M. Notably, Zevra Therapeutics's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zevra Therapeutics is 14.97x versus 3.54x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.